The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2022 | The role of autologous transplantation in young and fit patients with multiple myeloma in 2022
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, comments on the role of autologous hematopoietic stem cell transplantation (autoHSCT) in the treatment of young and fit patients with multiple myeloma in the era of novel immunotherapeutic agents. Prof. Mohty argues that the Phase III DETERMINATION study (NCT01208662) confirmed the role of autoHSCT as a standard of care in this patient population. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
